Ocaratuzumab

Drug Profile

Ocaratuzumab

Alternative Names: AME-133; AME-133v; LY 2469298

Latest Information Update: 05 Feb 2016

Price : $50

At a glance

  • Originator Applied Molecular Evolution
  • Developer Applied Molecular Evolution; MENTRIK Biotech
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Follicular lymphoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Follicular lymphoma; Non-Hodgkin's lymphoma; Rheumatoid arthritis

Most Recent Events

  • 04 Feb 2016 No development reported - Phase-I for Rheumatoid arthritis in USA (IV)
  • 04 Feb 2016 No development reported - Phase-II for Follicular lymphoma in Japan (IV)
  • 04 Feb 2016 No development reported - Phase-II for Non-Hodgkin's lymphoma in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top